Tara M Connelly1, Arthur S Berg2, Leonard R Harris1, John P Hegarty1, Francesca M Ruggiero3, Susan M Deiling1, David L Brinton1, Walter A Koltun4. 1. Department of Surgery, College of Medicine, The Pennsylvania State University, Hershey, Pennsylvania. 2. Department of Biostatistics, College of Medicine, The Pennsylvania State University, Hershey, Pennsylvania. 3. Department of Pathology, The Pennsylvania State University, College of Medicine, Hershey, Pennsylvania. 4. Department of Surgery, College of Medicine, The Pennsylvania State University, Hershey, Pennsylvania. Electronic address: wkoltun@hmc.psu.edu.
Abstract
BACKGROUND: The T-cell activation Rho GTPase-activating protein (TAGAP) gene has a regulatory role in T cell activation. We have previously suggested a correlation between the TAGAP-associated single nucleotide polymorphism rs212388 and protection from anal sepsis in Crohn's disease (CD) patients. The present study sought to evaluate TAGAP's expression in colonic tissue of CD patients with varying disease severity and location. MATERIALS AND METHODS: Five transverse, 17 left, and five sigmoid colectomy specimens from 27 CD patients with varying disease severity (16 male, mean age at diagnosis 26.4 ± 2.2 y) were evaluated for TAGAP messenger RNA expression. Fisher exact, Mann-Whitney, and Welch two-sample t-tests were used for statistical evaluation. Immunohistochemistry confirmed results. RESULTS: Patients with tissue demonstrating lower TAGAP messenger RNA expression (less than the overall mean) were younger at diagnosis (mean age 21.1 ± 6.3 versus 32.5 ± 13 y, P = 0.009). Increased TAGAP expression was seen in moderate or severely diseased tissue versus tissue with no or mild disease (RQ = 1.3 ± 0.34 versus 0.53 ± 0.09, P = 0.050). This was the most dramatic in the sigmoid colon (P = 0.041). TAGAP expression was increased in more distal tissue with a significant difference seen when comparing transverse versus sigmoid colon with moderate or severe disease (0.51 ± 0.14 versus 1.9 ± 0.37, P = 0.049). CONCLUSIONS: Colonic expression of TAGAP in CD patients varied according to disease severity and location, being the most elevated in patients with severe disease in the sigmoid colon. Whether changes in TAGAP expression are a result of disease response or inherent to the disease pathophysiology itself remains to be determined. This gene warrants further investigation for its role in CD.
BACKGROUND: The T-cell activation Rho GTPase-activating protein (TAGAP) gene has a regulatory role in T cell activation. We have previously suggested a correlation between the TAGAP-associated single nucleotide polymorphism rs212388 and protection from anal sepsis in Crohn's disease (CD) patients. The present study sought to evaluate TAGAP's expression in colonic tissue of CDpatients with varying disease severity and location. MATERIALS AND METHODS: Five transverse, 17 left, and five sigmoid colectomy specimens from 27 CDpatients with varying disease severity (16 male, mean age at diagnosis 26.4 ± 2.2 y) were evaluated for TAGAP messenger RNA expression. Fisher exact, Mann-Whitney, and Welch two-sample t-tests were used for statistical evaluation. Immunohistochemistry confirmed results. RESULTS:Patients with tissue demonstrating lower TAGAP messenger RNA expression (less than the overall mean) were younger at diagnosis (mean age 21.1 ± 6.3 versus 32.5 ± 13 y, P = 0.009). Increased TAGAP expression was seen in moderate or severely diseased tissue versus tissue with no or mild disease (RQ = 1.3 ± 0.34 versus 0.53 ± 0.09, P = 0.050). This was the most dramatic in the sigmoid colon (P = 0.041). TAGAP expression was increased in more distal tissue with a significant difference seen when comparing transverse versus sigmoid colon with moderate or severe disease (0.51 ± 0.14 versus 1.9 ± 0.37, P = 0.049). CONCLUSIONS: Colonic expression of TAGAP in CDpatients varied according to disease severity and location, being the most elevated in patients with severe disease in the sigmoid colon. Whether changes in TAGAP expression are a result of disease response or inherent to the disease pathophysiology itself remains to be determined. This gene warrants further investigation for its role in CD.
Authors: Hannah C D Esdal; Muhammad B Ghbeis; Daniel A Saltzman; Donavon Hess; Janet R Hume; Robyn C Reed; Susan A Berry; Eric Hoggard; Betsy Hirsch; Linda B Baughn; Lisa A Schimmenti Journal: Mol Syndromol Date: 2018-04-28
Authors: T Berge; I S Leikfoss; I S Brorson; S D Bos; C M Page; M W Gustavsen; A Bjølgerud; T Holmøy; E G Celius; J Damoiseaux; J Smolders; H F Harbo; A Spurkland Journal: Genes Immun Date: 2016-01-14 Impact factor: 2.676
Authors: Josefine Persson; Björn Andersson; Suzanne van Veen; Mariëlle C Haks; Ogonna Obudulu; Sara Torkzadeh; Tom H M Ottenhoff; Nelly Kanberg; Magnus Gisslén; Lars-Magnus Andersson; Ali M Harandi Journal: Mol Immunol Date: 2022-03-04 Impact factor: 4.407